Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

(2019) Jose I. Bernardino et al.   PLoS One

A safety evaluation of raltegravir for the treatment of HIV

(2017) Rosa de Miguel et al.   Expert Opinion On Drug Safety

Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity

(2016) Krishna Kumar Ganta et al.   CELL BIOLOGY AND TOXICOLOGY

Drug-Induced Mitochondrial Toxicity

(2016) Iain P. Hargreaves et al.   DRUG SAFETY

Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain

(2016) Robert W. Neijzen et al.   International Journal of Clinical Pharmacy

Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy

(2015) Maren I. Blonk et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Human Immunodeficiency Virus-1 (HIV-1)-Mediated Apoptosis: New Therapeutic Targets

(2014) Zukile Mbita et al.   Viruses-Basel

Differentially Altered Molecular Signature of Visceral Adipose Tissue in HIV-1–Associated Lipodystrophy

(2013) José M. Gallego-Escuredo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV Treatment and Associated Mitochondrial Pathology

(2013) Kristian Gardner et al.   TOXICOLOGIC PATHOLOGY

Effects of Rilpivirine on Human Adipocyte Differentiation, Gene Expression, and Release of Adipokines and Cytokines

(2012) Julieta Díaz-Delfín et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mitochondrial Evolution in HIV-Infected Children Receiving First- or Second-Generation Nucleoside Analogues

(2012) Constanza Morén et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients

(2012) Catherine Fagard et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial

(2011) Sébastien Gallien et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical perspective on antiretroviral drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine

(2010) Thomas N Kakuda et al.   ANTIVIRAL THERAPY

Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir

(2010) Rumi Minami et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse‐Transcriptase Inhibitor–Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)

(2009) Eugenia Negredo et al.   CLINICAL INFECTIOUS DISEASES

Genetic and Functional Mitochondrial Assessment of HIV-Infected Patients Developing HAART-Related Hyperlactatemia

(2009) Glòria Garrabou et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C

(2009) E. Vispo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts

(2008) E De Lazzari et al.   HIV MEDICINE

New treatment options for HIV salvage patients: An overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists

(2008) Amelia Hughes et al.   JOURNAL OF INFECTION